
Overview
Cancer diagnostics firm's Q4 revenue rose 19%, beating analyst expectations
Testing revenue grew 21% driven by Decipher and Afirma tests
Company recorded GAAP net income of $41.1 mln, up 705% yr/yr
Outlook
Veracyte expects 2026 revenue growth of 10% to 13%, reaching $570 mln to $582 mln
Company projects 2026 testing revenue to grow 14% to 16%, reaching $560 mln to $570 mln
Veracyte anticipates 2026 adjusted EBITDA margin of approximately 25%
Result Drivers
DECIPHER AND AFIRMA GROWTH - Testing revenue increased 21% driven by Decipher and Afirma tests
CASH GENERATION - Generated $52.6 million of cash from operations in Q4
Company press release: ID:nBwb1stcfa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $140.60 mln | $133.62 mln (12 Analysts) |
Q4 Net Income |
| $41.10 mln |
|
Q4 Gross Margin |
| 72.50% |
|
Q4 Adjusted Operating Expenses |
| $65.10 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Veracyte Inc is $50.00, about 40.1% above its February 24 closing price of $35.69
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 49 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.